Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Regional Outlook and Forecast, 2022

List of Tables

The Global Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 2.2% CAGR during the forecast period.

A digestive illness called gastroesophageal reflux disease (GERD) occurs when stomach contents, including acid, food, and liquids, leak into the esophagus. The lining of the esophagus is irritated, giving patients a burning feeling. Heartburn (reflux) and regurgitation are the primary esophageal symptoms defining GERD. Moreover, GERD may result in esophageal inflammation if ignored for a long time. It is linked to sleep problems and low quality of life.

Upper endoscopy, an ambulatory acid (PH) probe test, esophageal manometry, and X-rays are the primary methods used to diagnose it. Changing one's lifestyle and using regulated drugs might help manage certain conditions, but others may also need surgery or powerful medications. Burning in the chest, dysphagia, belching, epigastric discomfort, trouble swallowing, regurgitation of food or sour liquid, and a lump in the throat are typical indications and symptoms of the condition.

Moreover, acid reflux sufferers may have a persistent cough, laryngitis, wheezing, burning or painful throat sensations, increasing asthma, and sleep difficulties at night. In rare cases, persistent reflux may result in stricture, esophagitis, metaplasia, or malignancy. The lower esophageal sphincter's intrinsic pressure, the crural diaphragm's extrinsic compression of the LES, and the acute angle of His are hypothesized to make up the anti-reflux barrier. Transient LES relaxations (TLESRs), LES hypotension, and physical disruption of the esophagogastric junction (EGJ), or hiatus hernia, are the three most common causes of reflux.

TLESRs, which occur during swallows to allow the passage of a bolus from the esophagus into the stomach, are the most important mechanism of reflux in healthy subjects and a significant portion of GERD patients. They are also induced by secondary peristalsis, which starts from the mid-esophagus due to a vago-vagal reflex beginning with the activation of gastric receptors primarily located in the sub-cardiac region. As a result, the primary factor that causes a TLESR is stomach distension, often brought on by gastric air or the presence of food, which explains why TLESRs are mostly a postprandial event.

COVID-19 Impact Analysis

The COVID-19 pandemic affected the market negatively during the pandemic phase. COVID-19's effects on many aspects of human health have been extensively discussed since the start of the pandemic, and gastroesophageal reflux disease (GERD) is no exception. There was a worry that the virus may move beyond the GI (gastrointestinal) tract by generating symptoms in other organ systems, such as the respiratory system, through a gut-lung axis or by causing infection or inflammation. The gut, the body's biggest immunological organ, may be home to colonies of COVID-19 virus, which reproduces quickly. Because of the association between COVID-19 and GERD shown by such analysis and research, the market growth was hampered significantly.

Market Growth Factors

High intake of fast food causing digestive diseases

Fast food naturally raises the chance of bloating, stomach ulcers, and sometimes even stomach cancer since it includes a variety of hazardous substances, chemicals, and excessive amounts of salt. If the body absorbs more salt (from fast food), the sodium will retain more water, which may cause stomach pain and abdominal swelling or bloating. Fast food consumption among adults rose with wealth while decreasing with age. Fast food consumption was similar across men and women, with a more significant proportion of men eating it for lunch and a higher proportion of women eating it as a snack. The growing consumption of fast food globally will increase the cases of gastroesophageal reflux diseases and propel market growth.

The surging consumption of alcohol

Personal factors include age, gender, domestic circumstances, and socioeconomic status. Although no one risk factor predominates, those who are more vulnerable to alcohol-related problems are more likely to use alcohol. Less wealthy individuals have more significant health and social issues due to alcohol use than more affluent individuals. Studies have also shown that drinking alcohol increases the risk of gastroesophageal reflux disease. The growing use of alcohol will have an impact on the disease's overall prevalence and may help drive the gastroesophageal reflux diseases market expansion.

Market Restraining Factors

Some side effects associated with gastroesophageal reflux disease's medications

Antacids may cause allergies in certain persons and make it more likely for people to become allergic to certain foods. Antacid side effects are often caused by improper dosage. Several antacids include calcium, including Maalox, Mylanta, Rolaids, and Tums. A calcium overdose is possible if the patient takes them in excess or longer than recommended. Symptoms of too much calcium include nausea, vomiting, altered mental state, and kidney stones. Alkalosis may also result from too much calcium. The body can't produce enough acid in this state for it to work effectively. It might indicate another disease if the patient feels they need to take a lot of antacids to feel better.

Type Outlook

Based on type, the gastroesophageal reflux disease therapeutics market is segmented into antacids, H2 receptor blockers, proton pump inhibitors (PPIs) and pro-kinetic agents. The proton pump inhibitors (PPIs) segment acquired a significant revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is due to the fact that it is the most often recommended family of medications for treating heartburn and conditions linked to acidity. They work by inhibiting acid production in the stomach's parietal cells. Both over-the-counter and prescription PPIs are offered. Omeprazole and lansoprazole are two medications that have been around the longest and are thus the most well-known to doctors and patients.

Regional Outlook

Region-wise, the gastroesophageal reflux disease therapeutics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is owing to the increased incidence of GERD in the local population and the rising use of GERD therapies. Also, there are more and more campaigns to raise public awareness of the problem, driving up demand for GERD treatments. The campaign aimed to provide GERD sufferers with simple-to-follow recipes that are reflux-friendly.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

Antacids
Proton Pump Inhibitors (PPIs)
H2 Receptor Blockers
Pro-kinetic Agents

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Companies Profiled

AstraZeneca PLC
Eisai Co., Ltd.
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals, Inc.
Johnson & Johnson
Medigus Ltd.
Sebela Pharmaceuticals
Phathom Pharmaceuticals, Inc.
Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market, by Type
- 1.4.2 Global Gastroesophageal Reflux Disease Therapeutics Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market by Type

3.1 Global Antacids Market by Region
3.2 Global Proton Pump Inhibitors (PPIs) Market by Region
3.3 Global H2 Receptor Blockers Market by Region
3.4 Global Pro-kinetic Agents Market by Region

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market by Region

4.1 North America Gastroesophageal Reflux Disease Therapeutics Market
- 4.1.1 North America Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.1.1.1 North America Antacids Market by Country
  - 4.1.1.2 North America Proton Pump Inhibitors (PPIs) Market by Country
  - 4.1.1.3 North America H2 Receptor Blockers Market by Country
  - 4.1.1.4 North America Pro-kinetic Agents Market by Country
- 4.1.2 North America Gastroesophageal Reflux Disease Therapeutics Market by Country
  - 4.1.2.1 US Gastroesophageal Reflux Disease Therapeutics Market
    - 4.1.2.1.1 US Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.1.2.2 Canada Gastroesophageal Reflux Disease Therapeutics Market
    - 4.1.2.2.1 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.1.2.3 Mexico Gastroesophageal Reflux Disease Therapeutics Market
    - 4.1.2.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.1.2.4 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market
    - 4.1.2.4.1 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type
4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market
- 4.2.1 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.1.1 Europe Antacids Market by Country
  - 4.2.1.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
  - 4.2.1.3 Europe H2 Receptor Blockers Market by Country
  - 4.2.1.4 Europe Pro-kinetic Agents Market by Country
- 4.2.2 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
  - 4.2.2.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.2 UK Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.3 France Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.2.2.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
    - 4.2.2.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
4.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
- 4.3.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.1.1 Asia Pacific Antacids Market by Country
  - 4.3.1.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country
  - 4.3.1.3 Asia Pacific H2 Receptor Blockers Market by Country
  - 4.3.1.4 Asia Pacific Pro-kinetic Agents Market by Country
- 4.3.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country
  - 4.3.2.1 China Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.1.1 China Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.2 Japan Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.3 India Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.3.1 India Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.4 South Korea Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.4.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.5 Singapore Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.5.1 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.6 Malaysia Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.6.1 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.3.2.7 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
    - 4.3.2.7.1 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
4.4 LAMEA Gastroesophageal Reflux Disease Therapeutics Market
- 4.4.1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.1.1 LAMEA Antacids Market by Country
  - 4.4.1.2 LAMEA Proton Pump Inhibitors (PPIs) Market by Country
  - 4.4.1.3 LAMEA H2 Receptor Blockers Market by Country
  - 4.4.1.4 LAMEA Pro-kinetic Agents Market by Country
- 4.4.2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country
  - 4.4.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.1.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.2 Argentina Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.2.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.3 UAE Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.3.1 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.4 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.4.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.5 South Africa Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.5.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.6 Nigeria Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.6.1 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type
  - 4.4.2.7 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market
    - 4.4.2.7.1 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type

Chapter 5. Company Profiles

5.1 Takeda Pharmaceutical Company Limited
- 5.1.1 Company Overview
- 5.1.2 Financial Analysis
- 5.1.3 Regional Analysis
- 5.1.4 Research & Development Expense
5.2 AstraZeneca PLC
- 5.2.1 Company Overview
- 5.2.2 Financial Analysis
- 5.2.3 Regional Analysis
- 5.2.4 Research & Development Expenses
5.3 GlaxoSmithKline PLC (GSK)
- 5.3.1 Company Overview
- 5.3.2 Financial Analysis
- 5.3.3 Segmental and Regional Analysis
- 5.3.4 Research & Development Expense
5.4 Johnson & Johnson
- 5.4.1 Company Overview
- 5.4.2 Financial Analysis
- 5.4.3 Segmental &Regional Analysis
- 5.4.4 Research & Development Expenses
5.5 Ironwood Pharmaceuticals, Inc.
- 5.5.1 Company Overview
- 5.5.2 Financial Analysis
- 5.5.3 Regional Analysis
- 5.5.4 Research & Development Expenses
5.6 Eisai Co., Ltd.
- 5.6.1 Company Overview
- 5.6.2 Financial Analysis
- 5.6.3 Segmental and Regional Analysis
- 5.6.4 Research & Development Expenses
5.7 Medigus Ltd.
- 5.7.1 Company Overview
- 5.7.2 Financial Analysis
- 5.7.3 Segmental and Regional Analysis
- 5.7.4 Research & Development Expenses
5.8 Sebela Pharmaceuticals
- 5.8.1 Company Overview
- 5.8.2 Recent strategies and developments:
  - 5.8.2.1 Partnerships, Collaborations, and Agreements:
5.9 Phathom Pharmaceuticals, Inc.
- 5.9.1 Company Overview
- 5.9.2 Research & Development Expenses
- 5.9.3 Recent strategies and developments:
  - 5.9.3.1 Partnerships, Collaborations, and Agreements:
5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- 5.10.1 Company Overview
- 5.10.2 Recent strategies and developments:
  - 5.10.2.1 Product Launches and Product Expansions:

LIST OF TABLES

TABLE 1 Global Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 Global Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 Global Antacids Market by Region, 2018 - 2021, USD Million
TABLE 6 Global Antacids Market by Region, 2022 - 2028, USD Million
TABLE 7 Global Proton Pump Inhibitors (PPIs) Market by Region, 2018 - 2021, USD Million
TABLE 8 Global Proton Pump Inhibitors (PPIs) Market by Region, 2022 - 2028, USD Million
TABLE 9 Global H2 Receptor Blockers Market by Region, 2018 - 2021, USD Million
TABLE 10 Global H2 Receptor Blockers Market by Region, 2022 - 2028, USD Million
TABLE 11 Global Pro-kinetic Agents Market by Region, 2018 - 2021, USD Million
TABLE 12 Global Pro-kinetic Agents Market by Region, 2022 - 2028, USD Million
TABLE 13 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2021, USD Million
TABLE 14 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2022 - 2028, USD Million
TABLE 15 North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 16 North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 17 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 18 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 19 North America Antacids Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Antacids Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 23 North America H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 24 North America H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 25 North America Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 29 US Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 30 US Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 31 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 32 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 33 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 34 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 35 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 36 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 37 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 38 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 39 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 40 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 41 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 42 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 43 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 44 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 45 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 46 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 47 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 48 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 49 Europe Antacids Market by Country, 2018 - 2021, USD Million
TABLE 50 Europe Antacids Market by Country, 2022 - 2028, USD Million
TABLE 51 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 52 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 53 Europe H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 54 Europe H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 55 Europe Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 56 Europe Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 57 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 58 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 59 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 60 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 61 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 62 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 63 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 64 UK Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 65 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 66 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 67 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 68 France Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 69 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 70 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 71 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 72 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 73 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 74 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 75 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 76 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 77 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 78 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 79 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 80 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 81 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 82 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 83 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 84 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 87 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 88 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 89 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 90 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 91 Asia Pacific Antacids Market by Country, 2018 - 2021, USD Million
TABLE 92 Asia Pacific Antacids Market by Country, 2022 - 2028, USD Million
TABLE 93 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 94 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 95 Asia Pacific H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 96 Asia Pacific H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 97 Asia Pacific Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 98 Asia Pacific Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 99 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 100 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 101 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 102 China Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 103 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 104 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 105 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 106 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 107 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 108 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 109 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 110 India Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 111 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 112 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 113 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 114 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 115 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 116 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 117 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 118 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 119 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 120 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 121 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 122 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 123 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 124 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 125 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 126 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 127 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 128 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 129 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 130 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 131 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 132 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 133 LAMEA Antacids Market by Country, 2018 - 2021, USD Million
TABLE 134 LAMEA Antacids Market by Country, 2022 - 2028, USD Million
TABLE 135 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
TABLE 136 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
TABLE 137 LAMEA H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
TABLE 138 LAMEA H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
TABLE 139 LAMEA Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
TABLE 140 LAMEA Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
TABLE 141 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 142 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 143 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 144 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 145 2023
TABLE 146 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 147 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 148 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 149 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 150 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 151 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 152 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 153 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 154 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 155 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 156 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 157 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 158 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 159 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 160 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 161 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 162 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 163 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 164 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 165 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 166 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 167 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 168 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
TABLE 169 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
TABLE 170 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 171 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 172 Key Information - Takeda Pharmaceutical Company Limited
TABLE 173 KEY INFORMATION - AstraZeneca PLC
TABLE 174 Key Information - GlaxoSmithKline PLC
TABLE 175 Key information -Johnson & Johnson
TABLE 176 Key Information - Ironwood Pharmaceuticals, Inc.
TABLE 177 Key Information - Eisai Co., Ltd.
TABLE 178 Key Information - Medigus Ltd.
TABLE 179 Key Information - Sebela Pharmaceuticals
TABLE 180 Key Information - Phathom Pharmaceuticals, Inc.
TABLE 181 Key Information - Camber Pharmaceuticals, Inc.

List of Figures

FIG 1 Methodology for the research
FIG 2 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2021
FIG 3 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2028
FIG 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2028, USD Million
FIG 5 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2021
FIG 6 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2028
FIG 7 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2028, USD Million

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Regional Outlook and Forecast, 2022 - 2028

Description

Table of Contents